Comparable Simulation Models to Assess the Impact of Vehicle Transportation on Product Quality of mAb Dosing Solutions

Therapeutic monoclonal antibody (mAb) products for intravenous (IV) administration generally require aseptic compounding with a commercially available diluent. When the administration site is located away from the preparation site, the prepared dosing solution may need to be transported in a vehicle. The impact of vehicle transportation on product quality of mAbs needs to be evaluated to define safe handling and transportation conditions for dosing solutions. Designing and executing actual vehicle transportation studies requires considerable resources and time. In this study, we systematically developed three different laboratory equipment-based methods that simulate vehicle transportation stresses: Orbital Shaker (OS), Reciprocating Shaker (RS), and Vibration Test System (VTS) based simulation methods. We assessed their feasibility by comparing the impact on product quality caused by each simulated method with that caused by actual vehicle transportation. Without residual polysorbate 80 (PS80) in the mAb dosing solution, transportation via cargo van led to considerable increase in the subvisible particle counts and did not meet the compendial specifications for light obscuration method. However, the presence of as low as 0.0004 %w/v (4 ppm) PS80 in the dosing solution stabilized the mAb against vehicle transportation stresses and met the compendial specifications. Vehicle transportation of an IV bag with headspace resulted in negligible micro air bubbles and foaming in both PS80-free and PS80-containing mAb dosing solutions. These phenomena were found to be comparable with the VTS-based simulated method. However, the OS- and RS-based simulated methods formed significantly more micro air bubbles and foaming in an IV bag with headspace than either actual vehicle transportation or the VTS-based simulated method. Despite the higher interfacial stress (micro air bubbles and foaming) in the dosing solution created by the OS- and RS-based simulated methods, 0.0004 %w/v (4 ppm) PS80 in the dosing solution was found to be sufficient to stabilize the mAb. The study shows that, under appropriate simulated conditions, the OS-, RS-, and VTS-based simulated methods can be used as practical and meaningful models to assess the impact and risk of vehicle transportation on the quality of mAb dosing solutions.